federal_register: 2022-27022

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2022-27022 Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal Notice The Food and Drug Administration (FDA) is announcing the renewal of the Endocrinologic and Metabolic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Endocrinologic and Metabolic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2024, expiration date. 2022-12-14 2022 12 https://www.federalregister.gov/documents/2022/12/14/2022-27022/advisory-committee-endocrinologic-and-metabolic-drugs-advisory-committee-renewal https://www.govinfo.gov/content/pkg/FR-2022-12-14/pdf/2022-27022.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA) is announcing the renewal of the Endocrinologic and Metabolic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to...

Links from other tables